Navigation Links
ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors

IRVINE, Calif., April 4, 2011 /PRNewswire/ --ChromaDex Corporation (OTCBB: CDXC),an innovative natural products company that provides proprietary, science-based solutions and ingredients, today announced that Curtis A. Lockshin, Ph.D., was appointed to its Board of Directors.

Dr. Lockshin currently serves as a Director of Sorrento Therapeutics and the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Winston Pharmaceuticals. In addition to his board positions, he serves as a consultant to private companies in healthcare and biotechnology. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor's new leads initiative. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.

"Dr. Lockshin's deep experience with an array of science-based, regulated companies brings valuable perspective to our board," said Frank Jaksch, CEO and co-founder of ChromaDex. "As we convert our knowledge of natural compounds into innovative commercial products and applications targeted at the nutraceutical, food and beverage, cosmetic and pharmaceutical markets, we are committed to strengthening our management team and our board with the experience needed to reinforce our dedication to the science behind our natural ingredients."

About ChromaDex

ChromaDex™ is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has a strong pipeline of new compounds, including its pTeroPure™ pterostilbene on which it has worldwide, exclusive rights to patents pending.  ChromaDex is a publicly-traded life-sciences company (OTC stock symbol CDXC.OB).

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the company's Securities and Exchange Commission filings. The company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Inquiries
Liviakis Financial Communications, Inc.
John M. Liviakis, President

ChromaDex Contact
Jenny Robles

Media Contact
Carolyn Hawley
Canale Communications

SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
2. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
3. ChromaDex Launches pTeroPure Pterostilbene
4. ChromaDex Announces 2008 Year End Financial Results
5. ChromaDex Announces Second Quarter 2008 Financial Results
6. BioStorage Technologies Appoints New Director of Business Development for European Operations
7. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
8. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
9. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
10. Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality
11. OncoSec Medical Appoints Punit Dhillon as President and CEO
Post Your Comments:
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):